London-based Robinhood rival Freetrade buys UK arm of Australian investing platform Stake

London-based Robinhood rival Freetrade buys UK arm of Australian investing platform Stake


Key Points
  • British retail investing app Freetrade has entered into an agreement with Australian rival Stake to take on all of the company’s U.K. clients and their assets, Freetrade told CNBC Tuesday.
  • Sydney-based Stake launched its services in the U.K. in 2020, however the firm has decided to focus primarily on its Australia and New Zealand operations after a recent business review.
  • The move is expected to bolster Freetrade’s domestic operations, and comes as British retail investment platforms as a whole are facing heated competition from Robinhood.



Source

Stocks making the biggest moves midday: KKR, Blackstone, CrowdStrike, International Paper & more
Finance

Stocks making the biggest moves midday: KKR, Blackstone, CrowdStrike, International Paper & more

Check out the companies making the biggest moves midday: Financials — The financials sector of the S & P 500 slid more than 3% in midday trading, the worst performer in the broad market. Alternative asset managers KKR and Blackstone slid roughly 9% and 7%, respectively, after activist hedge fund Saba Capital Management and Cox […]

Read More
Bitcoin falls to nearly ,000 as 2026 crypto woes continue
Finance

Bitcoin falls to nearly $64,000 as 2026 crypto woes continue

Key Points Bitcoin traded as low as $64,830 early Monday. The token slid nearly 5% from Sunday to Monday, hitting at one point its lowest level in more than two weeks. Investors are rotating out of risk-on trades like bitcoin and turning to gold as confusion over Trump’s latest tariffs has spread and a war […]

Read More
Stocks making the biggest moves premarket: Arcellx, Novo Nordisk, Domino’s Pizza and more
Finance

Stocks making the biggest moves premarket: Arcellx, Novo Nordisk, Domino’s Pizza and more

Check out the companies making headlines before the bell. Arcellx — The biotech stock surged 78% after Gilead Sciences said Monday it agreed to acquire Arcellx for $7.8 billion, offering $115 per share in cash at closing and one contingent value right of $5 per share. Arcellx focuses on immunotherapies for patients with cancer and […]

Read More